Table 1 Comparison of estimated means and treatment differences for gastric emptying after 5 weeks of treatment

From: Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

Parameters

Liraglutide 1.8 mg n=30

Liraglutide 3.0 mg n=30

Placebo n=30

Treatment ratio (R) for 1liraglutide 1.8 mg vs placebo 2liraglutide 3.0 mg vs placebo 3liraglutide 3.0 vs 1.8 mg

P-value

Gastric emptying

 AUC0–300 min (min μg ml−1)

2193

2252

2424

  
    

1R: 0.90 (0.81; 1.01)

0.15

    

2R: 0.93 (0.83; 1.04)

0.28

 Primary end point:

   

3R: 1.03 (0.92; 1.15)

0.69

 AUC0–60 min (min μg ml−1)

299.4

265.2

343.1

  
    

1R: 0.87 (0.73; 1.05)

0.14

    

2R: 0.77 (0.64; 0.93)

0.007

    

3R: 0.89 (0.74; 1.06)

0.18

 Ratio AUC0–60 min/AUC0–300 min

0.13

0.12

0.14

  
    

1R: 0.94 (0.75; 1.18)

0.61

    

2R: 0.84 (0.67;1.05)

0.12

    

3R: 0.89 (0.71; 1.11)

0.29

 Cmax (μg ml−1)

10.5

11.4

11.8

  
    

1R: 0.90 (0.81; 0.99)

0.04

    

2R: 0.97 (0.87;1.07)

0.52

    

3R: 1.08 (0.97; 1.20)

0.14

  1. Abbreviation: CI, confidence interval.
  2. Data are estimated means. Treatment ratios are estimated means (95% CIs), except for primary end point AUC0–300 min , where they are estimated means (90% CIs). Comparisons between treatment groups were performed using the parametric linear mixed-effect model using log-transformed values. The model included effects of subject, period and treatment group (subject was included as a random effect).
Back to article page